

This announcement is not for release, publication or distribution in the United States, Canada, Australia or Japan. This announcement is not an offer of securities for sale in the United States or elsewhere.



To the Copenhagen Stock Exchange
Announcement No. 21-07 / Copenhagen, 21 June 2007

TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771

Offering closed for applications for shares

www.topotarget.com

As stated in TopoTarget A/S' offering circular of 4 June 2007, the subscription period closed as of today at 16.00 CET and therefore the applications for shares in the offering are now closed.

The result of the offering will be communicated in a stock exchange announcement which is expected to be released at the latest 8:30 CET on Friday 22 June 2007.

TopoTarget A/S

For further information please contact:

Dr. Peter Buhl Jensen	Phone	+45 39 17 83 41
Chief Executive Officer	Mobile	+45 21 60 89 22

Background information

About TopoTarget

TopoTarget (OMX – The Nordic Exchange: TOPO) is a biopharmaceutical company, headquartered in Denmark and with subsidiaries in the UK, Germany and the USA, dedicated to finding "Answers for Cancer" and developing improved cancer therapies. TopoTarget is founded and run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. Focus lies on highly predictive cancer models and key cancer enzyme regulators (mainly HDAC, mTOR, and topoisomerase II inhibitors) and a strong development foundation has been built. TopoTarget has a broad portfolio of small molecule preclinical drug candidates and seven drugs are in clinical development, including both novel anti-cancer therapeutics and new cancer indications for existing drugs. Savene™ is TopoTarget's first product on the market. In addition to organic growth, TopoTarget consistently looks for opportunities to strengthen and expand its activities through acquisitions and in-licensing. For more information, please refer to www.topotarget.com.